Terminated PHASE1 INTERVENTIONAL 9-arm NCT05652868

Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer

A Phase 1 Multicenter Dose Escalation and Dose Expansion Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer - KisMET-01

Sponsor: Mythic Therapeutics

Conditions Advanced Non-Small Cell Lung Cancer Advanced Non-Small Cell Non-Squamous Lung Cancer Advanced Non-Small Cell Squamous Lung Cancer NSCLC NSCLC Stage IIIB NSCLC Stage IV Non-Small Cell Lung Cancer

Interventions MYTX-011

Updated 23 times since 2023 Last updated: Dec 15, 2025 Started: Mar 23, 2023 Primary completion: Oct 31, 2025 Completion: Nov 7, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Business decision

A PHASE1 clinical study on Advanced Non-Small Cell Lung Cancer and Advanced Non-Small Cell Non-Squamous Lung Cancer, this trial is terminated or withdrawn. The trial is conducted by Mythic Therapeutics and has accumulated 23 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

23 versions recorded

Jan 2026 — Present [monthly]

Terminated PHASE1

Status: Recruiting → Terminated
Dec 2025 — Jan 2026 [monthly]

Recruiting PHASE1
Sep 2025 — Dec 2025 [monthly]

Recruiting PHASE1
Jul 2025 — Sep 2025 [monthly]

Recruiting PHASE1
Jun 2025 — Jul 2025 [monthly]

Recruiting PHASE1

▶ Show 18 earlier versions

Mar 2025 — Jun 2025 [monthly]

Recruiting PHASE1
Dec 2024 — Mar 2025 [monthly]

Recruiting PHASE1
Nov 2024 — Dec 2024 [monthly]

Recruiting PHASE1
Sep 2024 — Nov 2024 [monthly]

Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1
May 2024 — Jul 2024 [monthly]

Recruiting PHASE1
Apr 2024 — May 2024 [monthly]

Recruiting PHASE1
Mar 2024 — Apr 2024 [monthly]

Recruiting PHASE1
Dec 2023 — Mar 2024 [monthly]

Recruiting PHASE1
Nov 2023 — Dec 2023 [monthly]

Recruiting PHASE1
Oct 2023 — Nov 2023 [monthly]

Recruiting PHASE1
Sep 2023 — Oct 2023 [monthly]

Recruiting PHASE1
Aug 2023 — Sep 2023 [monthly]

Recruiting PHASE1
Jun 2023 — Aug 2023 [monthly]

Recruiting PHASE1
May 2023 — Jun 2023 [monthly]

Recruiting PHASE1
Apr 2023 — May 2023 [monthly]

Recruiting PHASE1
Mar 2023 — Apr 2023 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Jan 2023 — Mar 2023 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mythic Therapeutics

Data source: Mythic Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adelaide, Australia , Atlanta, United States , Barcelona, Spain , Blacktown, Australia , Bordeaux, France , Boston, United States , Busan, South Korea , Camperdown, Australia , Charleston, United States , Fairfax, United States and 34 more locations